A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Description

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients will receive either melflufen+dex or pomalidomide+dex.

Study Start Date

June, 13 2017

Estimated Completion Date

December 2021

Interventions

  • Drug: Dexamethasone
  • Drug: Melflufen
  • Drug: Pomalidomide

Study ID

Oncopeptides AB -- OP-103

Status

Recruiting

Trial ID

NCT03151811

Study Type

Interventional

Trial Phase

Phase 3

Enrollment Quota

450

Sponsor

Oncopeptides AB

Inclusion Criteria

    1. Male or female, age 18 years or older 2. A prior diagnosis of multiple myeloma with documented disease progression requiring further treatment at time of screening 3. Measurable disease defined as any of the following:
  • Serum monoclonal protein ? 0.5 g/dL by protein electrophoresis.
  • ? 200 mg/24 hours of monoclonal protein in the urine on 24-hour electrophoresis
  • Serum free light chain ? 10 mg/dL AND abnormal serum kappa to lambda free light chain ratio 4. Received 2-4 prior lines of therapy, including lenalidomide and a PI, either sequential or in the same line, and is refractory (relapsed and refractory or refractory) to lenalidomide in the last line. Refractory status to lenalidomide is defined as progression while on lenalidomide therapy or within 60 days of last dose, following at least 2 cycles of lenalidomide with at least 14 doses of lenalidomide per cycle. 5. Life expectancy of ? 6 months 6. Eastern Cooperative Oncology Group (ECOG) performance status ? 2. 7. Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to start of treatment. Participants must agree to ongoing pregnancy testing. All patients must be willing to comply with all requirements of the USA pomalidomide Risk Evaluation and Mitigation Strategy (REMS) program or the pomalidomide Pregnancy Prevention Plan (PPP). 8. Ability to understand the purpose and risks of the study and provide signed and dated informed consent. 9. 12-lead Electrocardiogram (ECG) with QT interval calculated by Fridericia Formula (QTcF) interval of ? 470 msec Fridericia Formula. 10. The following laboratory results must be met during screening and also immediately before study drug administration on Cycle 1 Day 1:
  • Absolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L)
  • Platelet count ? 75,000 cells/mm3 (75 x 109/L)
  • Hemoglobin ? 8.0 g/dl
  • Total Bilirubin ? 1.5 x upper limit of normal (ULN), or patients diagnosed with Gilberts syndrome, that have been reviewed and approved by the medical monitor.
  • Aspartate transaminase (AST /SGOT) and alanine transaminase (ALT/SGPT) ? 3.0 x ULN.
  • Renal function: Estimated creatinine clearance by Cockcroft-Gault formula ? 45 mL/min. 11. Must be able to take antithrombotic prophylaxis. 12. Must have, or be willing to have an acceptable central catheter. (Port a cath, peripherally inserted central catheter [PICC-line], or central venous catheter) (Insertion only required if randomized to Arm A).

Exclusion Criteria

    1. Primary refractory disease (i.e. never responded (? MR) to any prior therapy) 2. Evidence of mucosal or internal bleeding or platelet transfusion refractory 3. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. 4. Prior exposure to pomalidomide 5. Known intolerance to IMiDs. 6. Known active infection requiring parenteral or oral anti-infective treatment within 14 days of randomization. 7. Other malignancy diagnosed or requiring treatment within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in active surveillance. 8. Pregnant or breast-feeding females 9. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse compliance or follow-up evaluation 10. Known human immunodeficiency virus or active hepatitis C viral infection 11. Active hepatitis B viral infection (defined as HBsAg+).
  • Patients with prior hepatitis B vaccine are permitted (defined as HBsAg-, Anti-HBs+, Anti-HBc-).
  • Non-active hepatitis B (HBsAg-, Anti-HBs+, Anti-HBc+) may be enrolled at the discretion of the investigator after consideration of risk of reactivation. 12. Concurrent symptomatic amyloidosis or plasma cell leukemia 13. POEMS syndrome 14. Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to randomization. IMiDs, PIs and or corticosteroids within 2 weeks prior to randomization. Other investigational therapies and monoclonal antibodies within 4 weeks of randomization. Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to randomization 15. Residual side effects to previous therapy > grade 1 prior to randomization (Alopecia any grade and/or neuropathy grade 2 without pain are permitted) 16. Prior peripheral stem cell transplant within 12 weeks of randomization 17. Prior allogeneic stem cell transplantation with active graft-versus-host-disease. 18. Prior major surgical procedure or radiation therapy within 4 weeks of the randomization 19. Known intolerance to steroid therapy

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (60)

Study Location Distance Name Phone Email
US13 - Boston, Massachusetts 2.4 miles None None None
US13 - Boston, Massachusetts 2.4 miles None None None
US13 - Boston, Massachusetts 2.4 miles None None None
US13 - Boston, Massachusetts 2.4 miles None None None
US13 - Boston, Massachusetts 2.4 miles None None None
US04 - East Setauket, New York 143.7 miles None None None
US04 - East Setauket, New York 143.7 miles None None None
US04 - East Setauket, New York 143.7 miles None None None
US04 - East Setauket, New York 143.7 miles None None None
US04 - East Setauket, New York 143.7 miles None None None
US10 - Hawthorne, New York 164.3 miles None None None
US10 - Hawthorne, New York 164.3 miles None None None
US10 - Hawthorne, New York 164.3 miles None None None
US10 - Hawthorne, New York 164.3 miles None None None
US10 - Hawthorne, New York 164.3 miles None None None
US05 - New York, New York 184.8 miles None None None
US05 - New York, New York 184.8 miles None None None
US05 - New York, New York 184.8 miles None None None
US05 - New York, New York 184.8 miles None None None
US05 - New York, New York 184.8 miles None None None
US05 - New York, New York 184.8 miles None None None
US06 - Philadelphia, Pennsylvania 269.5 miles None None None
US06 - Philadelphia, Pennsylvania 269.5 miles None None None
US06 - Philadelphia, Pennsylvania 269.5 miles None None None
US07 - Canton, Ohio 545.3 miles None None None
US07 - Canton, Ohio 545.3 miles None None None
US14 - Cleveland, Ohio 549.6 miles None None None
US14 - Cleveland, Ohio 549.6 miles None None None
US14 - Cleveland, Ohio 549.6 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US09 - Greenville, North Carolina 577.7 miles None None None
US08 - Charleston, South Carolina 815.6 miles None None None
US08 - Charleston, South Carolina 815.6 miles None None None
US08 - Charleston, South Carolina 815.6 miles None None None
US08 - Charleston, South Carolina 815.6 miles None None None
US11 - Gainesville, Florida 1,081.3 miles None None None
US11 - Gainesville, Florida 1,081.3 miles None None None
US11 - Gainesville, Florida 1,081.3 miles None None None
US12 - Orange City, Florida 1,090.5 miles None None None
US12 - Orange City, Florida 1,090.5 miles None None None
US12 - Orange City, Florida 1,090.5 miles None None None
US02 - Watertown, South Dakota 1,310.5 miles None None None
US02 - Watertown, South Dakota 1,310.5 miles None None None
US02 - Watertown, South Dakota 1,310.5 miles None None None
US02 - Watertown, South Dakota 1,310.5 miles None None None
US02 - Watertown, South Dakota 1,310.5 miles None None None
US15 - Fort Sam Houston, Texas 1,766.2 miles None None None
US15 - Fort Sam Houston, Texas 1,766.2 miles None None None
US16 - Boise, Idaho 2,256.8 miles None None None
US16 - Boise, Idaho 2,256.8 miles None None None
US16 - Boise, Idaho 2,256.8 miles None None None
US17 - Tucson, Arizona 2,279.0 miles None None None
US01 - Fresno, California 2,589.7 miles None None None
US01 - Fresno, California 2,589.7 miles None None None
US01 - Fresno, California 2,589.7 miles None None None
US03 - Berkeley, California 2,687.0 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.